{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:25:35Z","timestamp":1776065135338,"version":"3.50.1"},"reference-count":27,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,14]]},"DOI":"10.1182\/bloodadvances.2021005859","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T22:05:10Z","timestamp":1642111510000},"page":"3201-3206","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["<i>TP53<\/i> mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-8508","authenticated-orcid":false,"given":"Roman R.","family":"Schimmer","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]},{"given":"Larisa V.","family":"Kovtonyuk","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]},{"given":"Nancy","family":"Klemm","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]},{"given":"Jonas","family":"Fullin","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]},{"given":"Sebastian M.","family":"Stolz","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]},{"given":"Jan","family":"Mueller","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]},{"given":"Francisco","family":"Caiado","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8286-2429","authenticated-orcid":false,"given":"Kari J.","family":"Kurppa","sequence":"additional","affiliation":[{"name":"3Institute of Biomedicine and MediCity Research Laboratories, University of Turku, Turku, Finland;"},{"name":"4Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University, Turku, Finland; and"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5451","authenticated-orcid":false,"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}]},{"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-0957","authenticated-orcid":false,"given":"Steffen","family":"Boettcher","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland;"},{"name":"2Comprehensive Cancer Center Zurich, Zurich, Switzerland;"}]}],"member":"234","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"issue":"9","key":"2022052715235152700_B1","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood."},{"issue":"7540","key":"2022052715235152700_B2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature."},{"issue":"6453","key":"2022052715235152700_B3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science."},{"issue":"8","key":"2022052715235152700_B4","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/leu.2008.143","article-title":"Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype","volume":"22","author":"Haferlach","year":"2008","journal-title":"Leukemia."},{"issue":"1","key":"2022052715235152700_B5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia."},{"issue":"6","key":"2022052715235152700_B6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med."},{"issue":"21","key":"2022052715235152700_B7","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med."},{"issue":"7","key":"2022052715235152700_B8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res."},{"issue":"10","key":"2022052715235152700_B9","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.3324\/haematol.2014.104760","article-title":"Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"99","author":"M\u00fcller-Thomas","year":"2014","journal-title":"Haematologica."},{"issue":"12","key":"2022052715235152700_B10","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget."},{"issue":"34","key":"2022052715235152700_B11","doi-asserted-by":"crossref","first-page":"55264","DOI":"10.18632\/oncotarget.10526","article-title":"Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome","volume":"7","author":"Jung","year":"2016","journal-title":"Oncotarget."},{"issue":"22","key":"2022052715235152700_B12","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer."},{"issue":"4","key":"2022052715235152700_B13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14455","article-title":"TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes","volume":"176","author":"Chang","year":"2017","journal-title":"Br J Haematol."},{"key":"2022052715235152700_B14","first-page":"3896","article-title":"Real world data on decitabine treatment in 296 patients with acute myeloid leukemia: outcome and impact of TP53 mutations","volume":"130","author":"Rollig","year":"2017","journal-title":"Blood."},{"issue":"12","key":"2022052715235152700_B15","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"D\u00f6hner","year":"2018","journal-title":"Leukemia."},{"issue":"10","key":"2022052715235152700_B16","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"10","key":"2022052715235152700_B17","doi-asserted-by":"crossref","first-page":"e0238795","DOI":"10.1371\/journal.pone.0238795","article-title":"Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine","volume":"15","author":"Bories","year":"2020","journal-title":"PLoS One."},{"issue":"20","key":"2022052715235152700_B18","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer."},{"issue":"3","key":"2022052715235152700_B19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.onc.1207175","article-title":"The absence of p53 is critical for the induction of apoptosis by 5-aza-2\u2032-deoxycytidine","volume":"23","author":"Nieto","year":"2004","journal-title":"Oncogene."},{"issue":"19","key":"2022052715235152700_B20","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.18632\/oncotarget.2441","article-title":"Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells","volume":"5","author":"Yi","year":"2014","journal-title":"Oncotarget."},{"key":"2022052715235152700_B21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J."},{"issue":"20","key":"2022052715235152700_B22","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood."},{"issue":"7","key":"2022052715235152700_B23","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia."},{"issue":"9","key":"2022052715235152700_B24","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/j.1349-7006.2011.01993.x","article-title":"Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes","volume":"102","author":"Uchida","year":"2011","journal-title":"Cancer Sci."},{"issue":"10","key":"2022052715235152700_B25","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1349-7006.2012.02386.x","article-title":"Phase I\/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan","volume":"103","author":"Oki","year":"2012","journal-title":"Cancer Sci."},{"issue":"2","key":"2022052715235152700_B26","doi-asserted-by":"crossref","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One."},{"issue":"7","key":"2022052715235152700_B27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3201\/1898782\/advancesadv2021005859.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3201\/1898782\/advancesadv2021005859.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T15:24:31Z","timestamp":1653665071000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/11\/3201\/483517\/TP53-mutations-confer-resistance-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005859","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}